

## Notice of Zealand's interim report for Q1 2016 and related conference call

---

- **On the day of release, Wednesday 18 May 2016 at 9.00am CET, Zealand's senior management will host a conference call. The conference call can be accessed via live audio webcast from Zealand's website. Kindly notice the time of the conference call.**

*Copenhagen, 4 May 2016* – Zealand confirms the release of its interim report for Q1 2016 on Wednesday 18 May 2016 in accordance with the company's financial calendar. The release can be expected in the morning.

### **Conference call on Wednesday, 18 May 2016 at 9.00am CET – Kindly notice the time**

On the day of release, Zealand's senior management will host a conference call at 9.00am CET to present the interim report for Q1 2016. Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, SVP and Chief Financial Officer, Adam Steensberg, SVP and Chief Medical and Development Officer and Hanne Leth Hillman, SVP and Head of IR and Communications. The presentation will be followed by a Q&A session.

The conference call will be conducted in English and the dial-in numbers are:

DK standard access	+45 38 32 28 69
UK and international	+44 (0) 20 3364 5381
US (free dial-in)	+1 718 354 1157

Kindly inform the operator of the following passcode: 4206940

A live audio webcast of the call including an accompanying slide presentation will be available via the following link, <http://edge.media-server.com/m/p/u2fanvb7>, accessible also from the Investor section of the company's website ([www.zealandpharma.com](http://www.zealandpharma.com)). Participants are advised to register for the webcast approximately 10 minutes before the start.

A replay of the event will be made available from the Investor section of Zealand's website following the call.



### **For further information, please contact:**

**Hanne Leth Hillman**, Senior Vice President, Investor Relations and Communications  
Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)



## About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel investigational medicines and a portfolio of products and projects under license collaborations with Sanofi, Helsinn and Boehringer Ingelheim.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi who markets the product globally (ex-US) as Lyxumia<sup>®</sup> and has it under regulatory review in the US. The license agreement with Sanofi covers also a fixed-ratio combination of lixisenatide with basal insulin glargine (Lantus<sup>®</sup>) under regulatory review in both the US and Europe.

Zealand's proprietary pipeline of product candidates includes: *ZP4207 (single-dose rescue treatment)* for acute, severe hypoglycemia (Phase II); *ZP1848* for Short Bowel Syndrome (Phase II); *ZP4207 (multiple-dose version)* for better hypoglycemia management in diabetes (Phase I); *ZP2929* for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: [www.zealandpharma.com](http://www.zealandpharma.com) or follow us on Twitter @ZealandPharma